Home » Stocks » GLUE

Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -43.85M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Monte Rosa Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 weeks ago - SEC

About GLUE

Monte Rosa Therapeutics is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically-relevant proteins. We have developed a proprietary protein degradation platform, called QuEEN, that enables us to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically-relevant proteins in a highly selective manner. We have utilized our QuEEN, platform to design ... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Markus Warmuth, M.D.
Employees
60
Stock Exchange
NASDAQ
Ticker Symbol
GLUE
Full Company Profile

Financial Performance

Financial Statements